ENVB - Latest News
Enveric Biosciences, Inc. (ENVB), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $788,056. Beta to the broader market is 1.14.
The article list below shows the most recent ENVB headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ENVB Headlines
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
businesswire.com - Jun 29, 2026
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplas
Enveric Biosciences Announces Participation in 2026 BIO International Convention
gurufocus.com - Jun 16, 2026
Enveric Biosciences (NASDAQ: ENVB) (âEnvericâ or the âCompanyâ), a biotechnology company advancing novel neuroplastogenic small-molecule thera
Enveric Biosciences Announces Participation in 2026 BIO International Convention
businesswire.com - Jun 16, 2026
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplas
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
businesswire.com - Jun 9, 2026
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplas
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
businesswire.com - Jun 2, 2026
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplas
How News Affects ENVB Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ENVB's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ENVB news questions
- What is the latest ENVB news headline?
- The most recent ENVB headline (Jun 29, 2026) is "Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ENVB news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ENVB news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ENVB options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.